This is the hover veil
Menu
Menu
Home
COVID-19
MPX
About the taskforce
About the guidelines
FAQs
News
Taskforce TV
Contact us
COVID-19
MPX
About the taskforce
About the guidelines
FAQs
News
Taskforce TV
Contact us
News
News
Communique
Video
Explainer
Media release
Topics
Abatacept
Aboriginal and Torres Strait Islander people
ACEIs/ARBs
ACEM
ACIPC
ACNN
Acute and Critical Care Panel
Adults
AHPA
Alex Poole
Alistair Miller
Allied Health Professions Australia
Amanda Gwee
Anakinra
Angiotensin 2 receptor agonist (C21)
Annie Synnot
Antenatal corticosteroids
Antibiotics
Anticoagulants
Anticoagulation
Antivirals
ANZ Guidelines
ANZICS
ANZJOG
ANZPID COVID-19 Clinical Reference Group
Apixaban
Aprepitant
ARC
ASCOT
ASHM
ASID
Aspirin
ATAGI
Australasian Sleep Association
Australia Day honours
Australia Day Honours List
Australian and New Zealand Society for Geriatric Medicine
Australian College of Midwives
Australian Commission on Safety and Quality in Health Care
Australian Living Evidence Consortium (ALEC)
Azithromycin
Baloxavir marboxil
Bamlanivimab
Bamlanivimab plus etesevimab
Baricitinib
Basic Life Support
Bebtelovimab
BESSI principles
Breastfeeding
Bromhexine hydrochloride
Budesonide
Burnet
Camostat mesilate
Canakinumab
Cardiac arrest
Cardiac Arrest Working Group
Cardiopulmonary resuscitation guidance
Care after COVID-19
Care after COVID-19 flowchart
Care of Children
Care of Older People and Palliative Care Panel
Caroline Homer
Casirivimab plus imdevimab (Ronapreve)
CD24c
CENA
Chemophrophylaxis
Chemoprophylaxis Panel
CHF
Children and adolescents
Chloroquine
Ciclesonide
Clinical flowcharts
CMCS
Cochrane Australia
Colchicine
COMET-ICE
Commonwealth Department of Health and Aged Care
Conditional recommendation
Consumer Panel
Consumer-centered care
Convalescent plasma
Corticosteroids
Corticosteroids (Inhaled)
COVID-19
COVID-19 COS
CPAP/HFNO
CPR
CPR Flowcharts
Critical Disease Panel
CT-P59 monoclonal antibody
Darunavir-cobicistat
Decision Tool
Definitions of disease severity
Definitions of disease severity and risk of disease
Delayed umbilical cord clamping
Dexamethasone
Disease-modifying treatments
DMTC Panel
Drug treatments
Drug treatments flowcharts
Drug Treatments Panel
Dutasteride
ECMO
Enisamium
Ensovibep
Episode 6
Equity Trustees
Expert Advisory Group
Extracorporeal membrane oxygenation
Eye protection
Face masks
Facebook
FAQs
Favipiravir
Flowchart
GIN
Global Commission on Evidence
Good practice statements
GPs
Guideline Leadership Group
Guidelines Leadership Group
HCW
High-flow nasal oxygen
Hospital and Acute Care Panel
Hydroxychloroquine
Hydroxychloroquine plus azithromycin
Hyperbaric oxygen therapy
Ian Potter Foundation
ICEG
Imatinib
Immunodulatory treatments table
Immunoglobulin
Immunoglobulin plus methylprednisolone
Immunosuppressed
Infection Control Expert Group (ICEG)
Infection Control Matters Podcast
Infection Prevention and Control (IPC) Panel
Infliximab
Interferon beta-1a
Interferon Gamma
Interferon β-1a (inhaled)
International Women's Day
Intravenous immunoglobulin
IPC
Ivermectin
Jason Roberts
Joanne Muller
Lancet
Leadership
Lenzilumab
Living Evidence
Long COVID
Lopinavir-ritonavir
Lorraine Anderson
Magnesium Sulfate
Management of cardiac arrest
Mark Morgan
Methods Advisor
Methods Chair
Michelle King
Mild COVID-19
MJA
Molnupiravir (Lagverio)
Monkeypox (MPX)
Monoclonal antibodies
Monoclonal antibody therapy
MPX
MPX Panel
Murray PHN
N-acetylcysteine
Naltrexone
National Clinical Evidence Taskforce
NCET
NCIRS
Neonatal
Neonates
New England Journal of Medicine
New Topics & Questions
NHMRC
NICE
Nicole Allard
Nirmatrelvir plus ritonavir (Paxlovid)
Non-invasive ventilation
NPS MedicineWise
Nutrition
Observational Data Working Group
Oestrogen containing therapies
Opaganib
Oral antivirals
P2/N95 respirators
Paediatric & Adolescent Care
Paediatric & Adolescent Care Panel
Paediatric and Adolescent Care
Paediatric Decision Tool
Paediatric Management
Paediatrics
Pain management
Palliative and Aged Care Panel
Palliative Care
Palliative Care Working Group
PANORAMIC
Pathways to Care
Paxlovid prescribing guide
Paxlovid rebound
Peginterferon lambda
Penny Burns
Personal Protective Equipment (PPE)
Peter Morley
PIMS-TS
Podcast
Post-acute COVID-19
Post-COVID-19
post-exposure prophylaxis
Post-viral symptoms
Postnatal
pre-exposure prophylaxis
Pregnancy and perinatal care
Pregnancy and Perinatal Panel
Pregnant & Postpartum women
Pregnant or breastfeeding women
Primary and Chronic Care Panel
Prone positioning
Proxalutimide
Psychosocial support
Pulse oximeters
Puspa Sherlock
RACGP
RANZCOG
RCTs
Rebecca Randall
RECOVERY Trial
Regdanvimab (Regkirona)
Regeneron
REMAP-CAP
Remdesivir (Veklury)
Respiratory
Respiratory management
Respiratory support
Risk classification tool
RMSANZ
Royal Australian College of Surgeons
Rural and remote care
Ruxolitinib
Sabizabulin
Samantha Chakraborty
Sarilumab
Senior Clinical Fellow
Senior Evidence Officer
severe-critical COVID-19
Simon Craig
Skin and wound care
SMS notifications
Sofosbuvir plus daclatasvir
Sotrovimab
Sotrovimab (Xevudy)
Special populations
Steering Committee
Steroids
Steve McGloughlin
subcutaneous casirivimab plus imdevimab
Subscription
Tari Turner
Taskforce funding update
TaskforceTV
Team Profile
Tecovirimat
Telmisartan
TGA
THANZ
The Alfred
The Conversation
Thromboembolism
Timing of surgery
Tixagevimab plus cilgavimab (Evusheld)
Tocilizumab
Tofacitinib
Tracheostomy
Treatment
TSANZ
Umifenovir
Unvaccinated
Vaccination
Vaccine
Vaccinia immune globulin (VIG)
Venous thromboembolism (VTE) prophylaxis
Videolaryngoscopy
Vitamin C
Vitamin D
VTE prophylaxis
Webinar
Zinc
Featured
COVID-19 Research Pipeline
STUDIES
Cochrane COVID-19 Study Register
205,745
Registered/ Published
RCT
s
covid-nma.com
4,597
Registered
780
Published
SYSTEMATIC REVIEWS
Prospero
7,632
Registered
As at 24 March 2023
Tweets by evidence_aus
FILTERED BY > Tocilizumab
Clear filter
Communique #55
17 December, 2021
Click for the latest Taskforce news:
Communique
Communique #52
29 October, 2021
Click for the latest Taskforce news:
Communique
Communique #48
5 August, 2021
WEEK IN REVIEW Taskforce amends remarks for Tocilizumab in response to critical shortage This week the Taskforce was alerted by the Therapeutic Goods Administration (TGA) to a global tocilizumab shortage...
Communique
Taskforce amends remarks for Tocilizumab in response to critical shortage
5 August, 2021
This week the Taskforce was alerted by the Therapeutic Goods Administration (TGA) to a global tocilizumab shortage for both COVID-19 treatment use and other indications. To help support...
News
EXPLAINER: What happens if I test positive to COVID-19?
19 July, 2021
With the recent COVID-19 outbreak in NSW and Victoria, it’s timely to revisit what happens if you test positive with COVID-19. With so much media commentary and coverage...
Explainer
Guidelines update, v38.3
13 May, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include the following changes to the evidence summary sections for: Convalescent plasma...
News
Communique #42
22 April, 2021
Message from the Chair and Executive Director Dear Colleagues We’ve just passed 12-months since the first publication of the Australian clinical guidelines for the care of people with COVID-19....
Communique
Communique #40
18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...
Communique
Guidelines update, v35.2
11 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The reference for one included study (Wang et al.) was...
News
Guidelines update, v35.1
4 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The references for REMAP-CAP and COVACTA (Rosas et al.) trials have...
News
Communique #39
25 February, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Tocilizumab upgraded to conditional recommendation The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated...
Communique
RECOVERY Trial publishes tocilizumab results
12 February, 2021
The Taskforce notes the publication of results of the tocilizumab arm of the RECOVERY trial in medRxiv Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results...
News
Communique #38
11 February, 2021
Message from the Taskforce Chair Dear colleagues As we enter the second year of the COVID-19 pandemic it is timely to acknowledge the important role of the Taskforce’s...
Communique
Communique #37
29 January, 2021
Following a well-earned break, the Taskforce team has now returned to full capacity. Global evidence surveillance continued throughout January, with six clinical panel meetings held since January 11....
Communique
Taskforce recommendation for tocilizumab unchanged
29 January, 2021
The Taskforce Disease Modifying Treatments and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated the results of the tocilizumab arm of the REMAP-CAP trial (published as a pre-print on January 7,...
News
